TY - JOUR
T1 - A novel scheme of dystrophin disruption for the progression of advanced heart failure
AU - Kawada, Tomie
AU - Masui, Fujiko
AU - Tezuka, Asaki
AU - Ebisawa, Takashi
AU - Kumagai, Hiroyuki
AU - Nakazawa, Mikio
AU - Toyo-Oka, Teruhiko
N1 - Funding Information:
This study was financially supported by the Ministry of Education, Science, Sports and Culture, Japan, and the Translational Project in Ministry of Welfare and Labor, Japan, the Mitsubishi Research Foundation and the Motor Vehicle Foundation.
PY - 2005/8/1
Y1 - 2005/8/1
N2 - The precise mechanism of the progression of advanced heart failure is unknown. We assessed a new scheme in two heart failure models: (I) congenital dilated cardiomyopathy (DCM) in TO-2 strain hamsters lacking δ-sarcoglycan (SG) gene and (II) administration of a high-dose of isoproterenol, as an acute heart failure in normal rats. In TO-2 hamsters, we followed the time course of the histological, physiological and metabolic the progressions of heart failure to the end stage. Dystrophin localization detected by immunostaining age-dependently to the myoplasm and the in situ sarcolemma fragility evaluated by Evans blue entry was increased in the same cardiomyocytes. Western blotting revealed a limited cleavage of the dystrophin protein at the rod domain, strongly suggesting a contribution of endogenous protease(s). We found a remarkable up-regulation of the amount of calpain-1 and -2, and no change of their counterpart, calpastatin. After supplementing TO-2 hearts with the normal δ-SG gene in vivo, these pathological alterations and the animals' survival improved. Furthermore, dystrophin but not δ-SG was disrupted by a high dose of isoproterenol, translocated from the sarcolemma to the myoplasm and fragmented. These results of heart failure, irrespective of the hereditary or acquired origin, indicate a vicious cycle formed by the increased sarcolemma permeability, preferential activation of calpain over calpastatin, and translocation and cleavage of dystrophin would commonly lead to advanced heart failure.
AB - The precise mechanism of the progression of advanced heart failure is unknown. We assessed a new scheme in two heart failure models: (I) congenital dilated cardiomyopathy (DCM) in TO-2 strain hamsters lacking δ-sarcoglycan (SG) gene and (II) administration of a high-dose of isoproterenol, as an acute heart failure in normal rats. In TO-2 hamsters, we followed the time course of the histological, physiological and metabolic the progressions of heart failure to the end stage. Dystrophin localization detected by immunostaining age-dependently to the myoplasm and the in situ sarcolemma fragility evaluated by Evans blue entry was increased in the same cardiomyocytes. Western blotting revealed a limited cleavage of the dystrophin protein at the rod domain, strongly suggesting a contribution of endogenous protease(s). We found a remarkable up-regulation of the amount of calpain-1 and -2, and no change of their counterpart, calpastatin. After supplementing TO-2 hearts with the normal δ-SG gene in vivo, these pathological alterations and the animals' survival improved. Furthermore, dystrophin but not δ-SG was disrupted by a high dose of isoproterenol, translocated from the sarcolemma to the myoplasm and fragmented. These results of heart failure, irrespective of the hereditary or acquired origin, indicate a vicious cycle formed by the increased sarcolemma permeability, preferential activation of calpain over calpastatin, and translocation and cleavage of dystrophin would commonly lead to advanced heart failure.
KW - Calpain
KW - Dystrophin
KW - Gene therapy
KW - Heart failure
KW - Proteolysis
KW - δ-Sarcoglycan (SG)
UR - http://www.scopus.com/inward/record.url?scp=22744444453&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22744444453&partnerID=8YFLogxK
U2 - 10.1016/j.bbapap.2005.01.001
DO - 10.1016/j.bbapap.2005.01.001
M3 - Article
C2 - 16054019
AN - SCOPUS:22744444453
SN - 1570-9639
VL - 1751
SP - 73
EP - 81
JO - BBA - Protein Structure
JF - BBA - Protein Structure
IS - 1
ER -